临床试验的途径。
Gateways to clinical trials.
作者信息
Bayes M, Rabasseda X, Prous J R
机构信息
Prous Science, Barcelona, Spain.
出版信息
Methods Find Exp Clin Pharmacol. 2006 Jul-Aug;28(6):379-412.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs:(R)-Flurbiprofen, 90Yttrium-DOTA-huJ591; ABT-510, ACP-103, Ad5-FGF4, adalimumab, ademetionine, AG-7352, alemtuzumab, Amb a 1 ISS-DNA, anakinra, apaziquone, aprepitant, aripiprazole, atazanavir sulfate; BAL-8557, bevacizumab, BMS-188797, bortezomib, bosentan, brivudine; Calcipotriol/betamethasone dipropionate, cannabidiol, caspofungin acetate, catumaxomab, CERE-120, cetuximab, ciclesonide, cilomilast, cizolirtine citrate, Cypher, cystemustine; Dalbavancin, darifenacin hydrobromide, dasatinib, deferasirox, denosumab, desmoteplase, dihydrexidine, dimethyl fumarate, dutasteride, DW-166HC; Eculizumab, enfuvirtide, entecavir, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, eszopiclone, etoricoxib, everolimus; Fallypride, febuxostat, fenretinide, fesoterodine, fingolimod hydrochloride; Gabapentin enacarbil, gefitinib; hMaxi-K, human papillomavirus vaccine, HYAL-CT1101; Imatinib mesylate, indiplon, inolimomab, ISAtx-247; J591; Lacosamide, landiolol, lasofoxifene tartrate, lestaurtinib, lidocaine/prilocaine, linezolid, lixivaptan, lonafarnib, lopinavir, lopinavir/ritonavir, lumiracoxib; Natalizumab, nesiritide; OC-108, omalizumab, onercept, OSC; Palifermin, palonosetron hydrochloride, parathyroid hormone (human recombinant), parecoxib sodium, PD-MAGE-3 vaccine, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, pegsunercept, pelitinib, pitavastatin calcium, plerixafor hydrochloride, posaconazole, prasterone sulfate, pregabalin; Ramelteon, ranelic acid distrontium salt, rasburicase, rosuvastatin calcium, rotigotine, RSD-1235, rufinamide, rupatadine fumarate; Sarizotan hydrochloride, SHL-749, sirolimus-eluting stent, solifenacin succinate, sunitinib malate; Tadalafil, talampanel, tasidotin hydrochloride, Taxus, tegaserod maleate, telavancin hydrochloride, tenofovir disoproxil fumarate, tiotropium bromide, tocilizumab, tositumomab, treprostinil sodium, tridolgosir hydrochloride, TTS-CD3; Ularitide; Valdecoxib, Val-Tyr sardine peptidase, vardenafil hydrochloride hydrate, voriconazole; Yttrium (90Y) edotreotide, Yttrium 90 (90Y) ibritumomab tiuxetan; Zileuton, zucapsaicin.
《临床试验指南》是当前文献和会议中最新临床试验的指南。以下表格中的数据取自药物研发门户网站Prous Science Integrity的临床试验知识领域，网址为http://integrity.prous.com。本期重点关注以下几种药物：（R）-氟比洛芬、钇-90-DOTA-huJ591；ABT-510、ACP-103、Ad5-FGF4、阿达木单抗、腺苷蛋氨酸、AG-7352、阿仑单抗、Amb a 1 ISS-DNA、阿那白滞素、阿帕醌、阿瑞匹坦、阿立哌唑、硫酸阿扎那韦；BAL-8557、贝伐单抗、BMS-188797、硼替佐米、波生坦、溴夫定；卡泊三醇/倍他米松二丙酸酯、大麻二酚、醋酸卡泊芬净、卡妥索单抗、CERE-120、西妥昔单抗、环索奈德、西洛司特、柠檬酸西佐利定、西罗莫司洗脱支架、环磷酰胺；达巴万星、氢溴酸达非那新、达沙替尼、地拉罗司、地诺单抗、去氨普酶、二氢埃托啡、富马酸二甲酯、度他雄胺、DW-166HC；依库珠单抗、恩夫韦肽、恩替卡韦、依帕珠单抗、盐酸厄洛替尼、草酸艾司西酞普兰、艾司佐匹克隆、依托考昔、依维莫司；法利帕利德、非布索坦、芬维A酸、非索罗定、盐酸芬戈莫德；加巴喷丁酯、吉非替尼；hMaxi-K、人乳头瘤病毒疫苗、HYAL-CT1101；甲磺酸伊马替尼、因地普隆、依诺利单抗、ISAtx-247；J591；拉科酰胺、兰地洛尔、酒石酸拉索昔芬、来他替尼、利多卡因/丙胺卡因、利奈唑胺、利伐普坦、洛那法尼、洛匹那韦、洛匹那韦/利托那韦、氯美昔布；那他珠单抗、奈西立肽；OC-108、奥马珠单抗、奥尼西普、OSC；帕利夫明、盐酸帕洛诺司琼、甲状旁腺激素（重组人）、帕罗昔布钠、PD-MAGE-3疫苗、聚乙二醇化非格司亭、聚乙二醇化干扰素α-2a、聚乙二醇化干扰素α-2b、聚乙二醇化沙格司亭、培利替尼、匹伐他汀钙、盐酸普乐沙福、泊沙康唑、硫酸普拉睾酮、普瑞巴林；雷美替胺、雷尼酸锶盐、拉布立酶、瑞舒伐他汀钙、罗替戈汀、RSD-1235、卢非酰胺、富马酸卢帕他定；盐酸沙立佐坦、SHL-749、西罗莫司洗脱支架、琥珀酸索利那新、苹果酸舒尼替尼；他达拉非、他拉莫泮、盐酸他西多汀、紫杉醇洗脱支架、马来酸替加色罗、盐酸特拉万星、富马酸替诺福韦二吡呋酯、噻托溴铵、托珠单抗、托西莫单抗、曲前列尼尔钠、盐酸曲多戈西尔、TTS-CD3；乌拉立肽；伐地昔布、Val-Tyr沙丁鱼肽酶、水合盐酸伐地那非、伏立康唑；钇（90Y）依多曲肽、钇90（90Y）替伊莫单抗；齐留通、辣椒素。
Zotero 插件